{"id":392787,"date":"2025-12-17T16:45:00","date_gmt":"2025-12-17T16:45:00","guid":{"rendered":"https:\/\/dailybanglanewspapers.com\/news\/transgene-to-participate-in-upcoming-investor-meetings\/"},"modified":"2025-12-17T16:45:00","modified_gmt":"2025-12-17T16:45:00","slug":"transgene-to-participate-in-upcoming-investor-meetings","status":"publish","type":"post","link":"https:\/\/dailybanglanewspapers.com\/news\/transgene-to-participate-in-upcoming-investor-meetings\/","title":{"rendered":"Transgene to Participate in Upcoming Investor Meetings"},"content":{"rendered":"<p><\/p>\n<div id=\"main-body-container\" itemprop=\"articleBody\">\n<p align=\"justify\"><b>Strasbourg (France), December 17, 2025, 17:45 p.m. CET \u2013 Transgene<\/b> (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, <b>today<\/b> <b>announced that its management team will meet institutional investors during the upcoming editions of<\/b>:<\/p>\n<ul>\n<li style=\"margin-top:0cm; margin-bottom:8pt;\">LifeSci Partners Corporate Access Event (by <i>LifeSci Partners<\/i>), on <b>January 12 and 13, 2026<\/b>, in San Francisco (United States) in conjunction with the JP Morgan Healthcare Conference;<\/li>\n<li style=\"margin-top:0cm; margin-bottom:0cm;\">Biomed Forum (by <i>Allinvest Securities<\/i>), on<b> January 29, 2026<\/b>, in Paris (France).<\/li>\n<\/ul>\n<p align=\"center\">***<\/p>\n<p><b><i>Contacts <\/i><\/b><\/p>\n<table style=\"border-collapse: collapse; border-collapse:collapse ;\">\n<tr>\n<td style=\"width:385px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Transgene:<\/b><\/td>\n<td style=\"width:227.27px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>\u00a0<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"width:385px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Media:<\/b><\/td>\n<td style=\"width:227.27px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Investors &amp; Analysts:<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"width:385px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Caroline Tosch<\/b><\/td>\n<td style=\"width:227.27px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Lucie Larguier<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"width:385px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Corporate and Scientific Communications Manager<\/td>\n<td style=\"width:227.27px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Chief Financial Officer (CFO)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:385px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \">+33 (0)3 68 33 27 38<\/td>\n<td style=\"width:227.27px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Nadege Bartoli<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"width:385px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/12\/17\/3207183\/0\/en\/mailto:communication@transgene.fr\" rel=\"nofollow\" target=\"_blank\" title=\"communication@transgene.fr\">communication@transgene.fr<\/a><\/td>\n<td style=\"width:227.27px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Investor Relations Analyst<br \/>and Financial Communications Officer<\/td>\n<\/tr>\n<tr>\n<td style=\"width:385px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>MEDiSTRAVA<\/b><\/td>\n<td style=\"width:227.27px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \">+33\u00a0(0)3\u00a088\u00a027\u00a091 00\/03<\/td>\n<\/tr>\n<tr>\n<td style=\"width:385px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Frazer Hall\/Sylvie Berrebi<\/b><\/td>\n<td style=\"width:227.27px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/12\/17\/3207183\/0\/en\/mailto:investorrelations@transgene.fr\" rel=\"nofollow\" target=\"_blank\" title=\"investorrelations@transgene.fr\">investorrelations@transgene.fr<\/a><\/td>\n<\/tr>\n<tr>\n<td style=\"width:385px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \">+ 44 (0)203\u00a0928\u00a06900<\/td>\n<td style=\"width:227.27px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:385px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/12\/17\/3207183\/0\/en\/mailto:transgene@medistrava.com\" rel=\"nofollow\" target=\"_blank\" title=\"transgene@medistrava.com\">transgene@medistrava.com<\/a><\/td>\n<td style=\"width:227.27px;;text-align: justify ;  vertical-align: middle; vertical-align: top ; \">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\"><b><i>About Transgene<\/i><\/b><br \/>Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company\u2019s clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the <i>myvac<\/i>\u00ae platform is the Company\u2019s lead asset, with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. The Company has other viral vector-based assets, including BT-001, an oncolytic virus based on the Invir.IO\u00ae viral backbone, which is in clinical development. The Company also conducts innovative discovery and preclinical work, aimed at developing novel viral vector-based modalities. <br \/>With Transgene\u2019s <i>myvac<\/i>\u00ae platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The <i>myvac<\/i>\u00ae approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations, identified and selected through advanced Artificial Intelligence technologies.<br \/>With its proprietary platform Invir.IO\u00ae, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.<br \/>Additional information about Transgene is available at: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nfUoi_Tc-7h5x9OUPu2hXKCk1xF-kqdiLllP69eEW06J7ZpWSGifBbW4W8-p0Oi8NqS97jAJc4YsCzl2pVHD1tpFkUiwNiN9-A7fAHaKxS0=\" rel=\"nofollow\" target=\"_blank\" title=\"www.transgene.com\">www.transgene.com<\/a><br \/>Follow us on social media: X : <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0jfbysC07lAI4bPe9-iebWtkBRxs-I5ho22fQ12wFrHO2-RjlPzEvgTMjPJmUDFISvSINjFG-Jer0uR9bQNS-A==\" rel=\"nofollow\" target=\"_blank\" title=\"@TransgeneSA\">@TransgeneSA<\/a> \u2014 LinkedIn: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0jfbysC07lAI4bPe9-iebYYX9GkwMbhyrkckAV47sGvSCmvU2saqTv4BJ37ITvgwZSaR8GE6waDeGhgJeEIpYPcLZitWdzZJcwU_JpMOENUo35uVlxMMG0mMEADq1ATK4fHdVmFaYKDDYwrIM47snA==\" rel=\"nofollow\" target=\"_blank\" title=\"@Transgene\">@Transgene<\/a> \u2014 Bluesky: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0jfbysC07lAI4bPe9-iebRPhMpObNhdJm1lTaRDeFxUt3kEmBsLc3_-DXU0bapbGeTWhIeU2FSys1ExbCAUjKLzHUxYZ7y01pUFivYMRFOR3ipE6z2kmxdotXLzPLb35\" rel=\"nofollow\" target=\"_blank\" title=\"@Transgene\">@Transgene<\/a><\/p>\n<p align=\"justify\"><b><i>Disclaimer <\/i><\/b><br \/><i>This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company\u2019s activities, perspectives, financial situation, results, regulatory authorities\u2019 agreement with development phases, and development. The Company\u2019s ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and\/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company\u2019s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (\u201cFacteurs de Risque\u201d) section of the Universal Registration Document, available on the AMF website (http:\/\/www.amf-france.org) or on Transgene\u2019s website (www.transgene.com). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.<\/i><\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=dsxFWvfHIYs-2Q1k5-e5UijBSjkl7QRyysvBdvO_Zb05n8Byx39VFdmqIG3vgql8o7oMI5mMK51kAQuNMvD9vJdFasjtgcuDeXCmILgtG2Tr4AQ4pCZnA66CDpkZ3j4_Wur0UoWAF83mSwhvT3-kF5jxukoy13hJQyw6hDqDpw3E2gFfDRcboYrfbCtjpUXR3WBpvpBBEjZeY4i8zBo2KRROC_eFucXlyXHqLNz0juo=\" title=\"20251217_Transgene_Next-Upcoming-Investor-Meetings_EN\" rel=\"nofollow\">20251217_Transgene_Next-Upcoming-Investor-Meetings_EN<\/a>\n      <\/li>\n<\/ul>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/ZTc0MjljOWMtZTNmNi00N2U1LTg5NDItYTAwOWU0MmQ4YWM0LTEwMTE1NDQtMjAyNS0xMi0xNy1lbg==\/tiny\/Transgene-S-A-.png\" referrerpolicy=\"no-referrer-when-downgrade\"\/>\n            <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Strasbourg (France), December 17, 2025, 17:45 p.m. CET \u2013 Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will meet institutional investors during the upcoming editions of: LifeSci Partners Corporate Access Event (by LifeSci Partners), on January 12 and 13, [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":392788,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/1756ee11-a970-4a73-b790-db2156db8384","fifu_image_alt":"","footnotes":""},"categories":[57166],"tags":[],"class_list":["post-392787","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"_links":{"self":[{"href":"https:\/\/dailybanglanewspapers.com\/news\/wp-json\/wp\/v2\/posts\/392787","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailybanglanewspapers.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailybanglanewspapers.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailybanglanewspapers.com\/news\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/dailybanglanewspapers.com\/news\/wp-json\/wp\/v2\/comments?post=392787"}],"version-history":[{"count":0,"href":"https:\/\/dailybanglanewspapers.com\/news\/wp-json\/wp\/v2\/posts\/392787\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailybanglanewspapers.com\/news\/wp-json\/wp\/v2\/media\/392788"}],"wp:attachment":[{"href":"https:\/\/dailybanglanewspapers.com\/news\/wp-json\/wp\/v2\/media?parent=392787"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailybanglanewspapers.com\/news\/wp-json\/wp\/v2\/categories?post=392787"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailybanglanewspapers.com\/news\/wp-json\/wp\/v2\/tags?post=392787"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}